Kyntra Bio Inc. Common Stock (KYNB)
Stock · NASDAQ · Health Care
$4.93as of 10/16/2026
Price chart
Active signals
KYNB Signal Track Record
How signals performed across all stocks →What KYNB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -2.3% | 49% | October 2, 2026 |
| Bollinger Band BreakdownActive now | 21 | -2.9% | 43% | October 5, 2026 |
| Bollinger Band Breakout | 21 | +3.4% | 57% | August 20, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -1.4% | 46% | September 16, 2026 |
| Any 20-session window (baseline) | -2.7% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KYNB
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 34
- Website
- www.kyntrabio.com/home
Fundamentals
- 1-day range
- $4.85$5.5
- Market cap
- $28.26M
- P/E (trailing)
- 0.12
- P/E (forward)
- -0.34
- EPS (trailing)
- $45.30
- Dividend yield
- —
- Beta
- 1.06
- Avg. volume
- 19.2K
How Kyntra Bio Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 16, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Kyntra Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KYNBKyntra Bio Inc. Common Stock$4.85▼ 9.51%Market cap $28.26MP/E 0.12$5.34$11.65
- RMTIRockwell Medical Inc. Common Stock$7.43▼ 6.89%Market cap $28.26MP/E —$4.89$12.9
- GRCEGrace Therapeutics Inc. Common Stock$1.89▼ 3.08%Market cap $28.44MP/E —$1.79$5.18
- MIRAMIRA Pharmaceuticals Inc. Common Stock$0.632▼ 3.95%Market cap $28.50MP/E —$0.6$2.45
- ACTUActuate Therapeutics Inc. Common stock$0.605▲ 21.00%Market cap $29.43MP/E —$0.41$8.27
- ABVCABVC BioPharma Inc. Common Stock$0.918▼ 1.61%Market cap $27.09MP/E —$0.7069$3.07
- BCTXBriaCell Therapeutics Corp. Common Shares$3.4▼ 9.81%Market cap $30.01MP/E —$3.68$20.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KYNB Kyntra Bio Inc. Common Stock | $28.26M | 0.12 | $4.85 | ▼ 9.51% | $5.34$11.65 |
| RMTI Rockwell Medical Inc. Common Stock | $28.26M | — | $7.43 | ▼ 6.89% | $4.89$12.9 |
| GRCE Grace Therapeutics Inc. Common Stock | $28.44M | — | $1.89 | ▼ 3.08% | $1.79$5.18 |
| MIRA MIRA Pharmaceuticals Inc. Common Stock | $28.50M | — | $0.632 | ▼ 3.95% | $0.6$2.45 |
| ACTU Actuate Therapeutics Inc. Common stock | $29.43M | — | $0.605 | ▲ 21.00% | $0.41$8.27 |
| ABVC ABVC BioPharma Inc. Common Stock | $27.09M | — | $0.918 | ▼ 1.61% | $0.7069$3.07 |
| BCTX BriaCell Therapeutics Corp. Common Shares | $30.01M | — | $3.4 | ▼ 9.81% | $3.68$20.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Maxim Group Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $35benzinga · 10/13/2026
- Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of DirectorsYahoo · 10/1/2026
- Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41Benzinga · 9/17/2026
Insider Activity
Insider Actions →- David DeLucia · September 6, 2026 · Tax Withholding22 @ $8.55
- Thane Wettig · September 6, 2026 · Tax Withholding209 @ $8.55
- Maykin Ho · June 12, 2026 · Grant7.0K
- James A. Schoeneck · June 12, 2026 · Grant7.0K
- Michael Kauffman · June 12, 2026 · Grant7.0K
- EDWARDS JEFFREY L · June 12, 2026 · Grant7.0K
- David DeLucia · June 6, 2026 · Tax Withholding52 @ $6.71
- Thane Wettig · June 6, 2026 · Tax Withholding198 @ $6.71
- Thane Wettig · May 14, 2026 · Buy2.8K @ $7.09
Institutional Ownership
March 31, 2026
- Total shares held
- 1.10M
- Total value held
- $6.73M
- Institutional holders
- 30
- Unknown400.0K
- Unknown156.6K
- Unknown105.6K
- Unknown89.4K
- Unknown84.3K
- Unknown49.5K
- Unknown46.0K
- Unknown39.7K
- Unknown27.6K
- Unknown27.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Kyntra Bio Names Andrew Singer to Board
Kyntra Bio has added Andrew E. Singer, MBA, to its board of directors. The move expands the company’s leadership team and could bring new expertise to its strategic planning. The appointment follows the company’s ongoing efforts to strengthen governance and support its growth initiatives. Investors may view the change as a sign of continued focus on development and operational improvement.
Kyntra Bio Names Andrew Singer to Board. Kyntra Bio has added Andrew E. Singer, MBA, to its board of directors. The move expands the company’s leadership team and could bring new expertise to its strategic planning. The appointment follows the company’s ongoing efforts to strengthen governance and support its growth initiatives. Investors may view the change as a sign of continued focus on development and operational improvement.